Non-alcoholic steatohepatitis and liver transplantation

详细信息    查看全文

• 作者：Stefano Gitto^a ; ¹ ; Ranka Vukotic^b ; ¹ ; Giovanni Vitale^b ; Martina Pirillo^b ; Erica Villa^a ; Pietro Andreone^b ; ^{pietro.andreone@unibo.it" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Liver transplant ; Non-alcoholic fatty liver disease
• 刊名：Digestive and Liver Disease
• 出版年：2016
• 出版时间：June 2016
• 年：2016
• 卷：48
• 期：6
• 页码：587-591
• 全文大小：797 K

文摘

Non-alcoholic steatohepatitis is a growing liver-related health problem. In Europe, non-alcoholic fatty liver disease is the most usual reason of chronic liver illness while steatohepatitis, its progressive form, affects 1% of Europeans and North Americans. In the United States steatohepatitis-related cirrhosis is one of the main indications for liver transplant. A targeted stratification for patients waiting for transplant and affected by this disease is mandatory especially because of their increased cardiovascular and cancer risk. The adequate treatment of NAFLD is crucial for the reduction of the disease related morbidity and mortality. In post-transplant setting, the recurrent or de novo steatosis might seriously affect the allograft short- and long-term outcome. Many conditions can represent the basis of the post-transplant steatohepatitis: obesity, hyperlipidaemia, diabetes mellitus, arterial hypertension, immunosuppressant treatment, alcoholic habit and liver graft steatosis. Today, the only consolidated therapy is represented by a deep life-style intervention since the use of drug-based alternative strategies is still limited and a very few data are available for the post-transplant period. Targeted and personalized behaviour and pharmacological interventions have to be developed for both the pre- and post-transplant phase.